ABBV AbbVie Inc

AbbVie is a biopharmaceutical company best known for Humira, with a growing pipeline spanning immunology, oncology, and neuroscience. Sector: Healthcare.

AbbVie Inc (ABBV) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Looking at how effectively the company deploy capital, ROIC is 16.89%, WACC is 5.80%, and the economic spread is 11.10%. On balance, returns on invested capital exceed the cost of funding by a comfortable margin, which over time compounds favorably for long-term holders. Supporting metrics show ROE at 22.49% and ROA at 6.46%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

On valuation, the company registers trailing P/E of 88.49, forward P/E of 14.36, PEG of 0.80. Forward P/E is considerably lower than trailing, which indicates earnings estimates are pointing higher — a dynamic that makes current prices look more reasonable on a prospective basis. The PEG reading suggests the market is pricing growth conservatively — a dynamic that can be favorable if earnings estimates prove accurate. A current ratio reading of 0.67 suggests the company carries less short-term financial cushion than the broader market average. Taken together, the multiple and liquidity picture suggests a company that is priced for a constructive outcome — but where execution against earnings estimates will be the key determinant of whether that price is justified.

Across the three margin layers, gross margin sits at 70.93%, operating margin at 33.69%, and free cash flow margin at 29.13%. The gross margin reading is exceptional — a reliable indicator of competitively advantaged businesses. Operating margins this strong typically indicate a combination of pricing power, cost discipline, and operating leverage. Free cash flow conversion is exceptional, indicating the company that are self-funding and cash-generative well above average. The margin profile is consistently healthy, a pattern often associated with durable competitive position and execution quality.

Two key indicators frame the near-term view: TTM revenue growth of 10.04% a signal of steady demand without the volatility of high-growth names, while the estimated 12-month price change of 21.75%, where the target distribution indicates incremental upside rather than outsized repricing. The near-term return case is built on whether reported trends and analyst projections can remain close enough to make current prices look justified. Whether the setup resolves positively or negatively will depend as much on the macro backdrop as on the capacity of the company to deliver against current estimates. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The full scorecard here is hard to argue with: capital efficiency is strong, margins are healthy, and growth is being priced constructively.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.